曼彻斯特大学医学研究获得新突破,高新石墨烯研发将改进脑癌治疗方案

2018-09-20 MedSci MedSci原创

据曼彻斯特大学最新报道,曼大健康科学学院运用新型材料石墨烯,成功研发治疗脑癌的新型手术设备,通过蜂窝生物技术(Honeycomb Biotechnology)提高脑癌手术治愈率,有望在不久的未来成为脑癌患者的福音。


      据曼彻斯特大学最新报道,曼大健康科学学院运用新型材料石墨烯,成功研发治疗脑癌的新型手术设备,通过蜂窝生物技术(Honeycomb Biotechnology)提高脑癌手术治愈率,有望在不久的未来成为脑癌患者的福音。

        曼彻斯特大学健康科学学院的蜂窝生物技术研究团队创始人Christopher Bullock和Richard Fu带领研发团队,运用石墨烯电极特性,成功开发了新型的脑癌手术植入装置,为多形性胶质母细胞瘤提供了更有效的精准治疗方案。曼大健康科学学院的科学家们表示,通过手术植入这种新型的石墨烯电疗设备,结合其他治疗方式,未来能够将脑癌这一致命疾病转变为可控的慢性病


曼彻斯特大学健康科学学院的蜂窝生物技术研究团队

创始人Christopher Bullock(左)和Richard Fu(右)

        蜂窝生物技术研究团队创始人Richard Fu是曼彻斯特临床神经科学中心的专业研究员,也是英国国家卫生研究所(NIHR)的临床研究员。他表示:“多形性胶质母细胞瘤(GBM)现在仍然是一种致命的疾病。我们坚信,这项研发成果将会对脑癌患者的生活带来重大的积极影响。”

        曼彻斯特大学健康科学学院的研究团队也凭借这款最新问世的石墨烯植入设备于今年8月获得了2018年Eli 和Britt Harari 石墨烯企业大奖(Eli and Britt Harari Graphene Enterprise Award),并获得了50,000英镑奖金,未来将用于石墨烯脑癌手术植入治疗装备的进一步研发,并推动其在临床的运用。

       另一位创始人Christopher Bullock是来自曼彻斯特大学健康科学学院的生物医学工程师,致力于研究石墨烯在医疗临床领域的运用,他即将在今年秋天,获得曼彻斯特大学研究石墨烯生物材料的博士学位。他补充到:“我们非常感谢Eli和Britt Harari的慷慨资助以及曼彻斯特大学的支持,这使得我们能够将虚幻的想法变成具有实践意义的发明。”

超级材料石墨烯

       2004年诞生于曼彻斯特大学的石墨烯是世界上第一种二维材料,比人类头发薄一百万倍,柔韧,透明,更具导电性。没有其他材料能够具有与石墨烯相同的性能,使其成为无数应用的理想材料。

 

石墨烯是地球上最薄的材料,它的强度是钢的200倍,是一种超轻量材料

 

医疗与健康科学科研实力雄厚

 

      除了领跑全球石墨烯科研领域,曼彻斯特大学同样深耕与医疗科研,不仅拥有雄厚的科研实力,更积累了深厚的行业经验。本年度石墨烯企业大奖归属于医疗科学与健康项目,充分彰显了曼彻斯特大学在医疗健康领域的科研实力。

 

      曼彻斯特大学在全球健康产业的先锋地位和深厚的行业资源享誉全球。曼彻斯特大学商学院借势学院前沿科研实力、深厚的行业基础,结合在医疗行业管理教育领域经验,为所有医疗及相关领域的业界人士提供了研究生专业的深造机会——国际医疗行业领导力在职硕士课程,通过学术研究和实践操作,帮助医疗健康领域专业人才应对当下全球行业挑战,以重塑医疗服务产业。

项目纵览

国际医疗行业领导力硕士课程旨在为全球医疗保健领域的领导者提供实践前沿的知识结构和实战经验。通过两年的在职教育,加深学员的专业学科领域的科研能力,提高管理技能和领导力,激发学习和创新潜力,提升在行业内的影响力,帮助企业加速健康成长,为全球社区创造丰富的公共价值,助推医疗产业的高速发展

点击http://uom.ac.cn/programmes/ihl 获得更多项目信息。

您是否渴望把握世界前沿行业趋势,在行业竞争中立于不败之地?你是否希望拓展全球国际医疗健康产业人脉,获取国际尖端医疗产业资讯?

国际医疗行业领导力在职硕士项目2019年3月班现已全面启动!如今,在曼彻斯特大学中国中心您就有机会获益于曼彻斯特大学卓越的医疗健康专业高等教学,让你不出国门成为领军型行业精英!

       2018年9月28日,对话国际医疗行业领导力在职硕士项目主任,成为医疗健康产业领军者!曼彻斯特大学国际医疗行业领导力在职硕士项目主任Stephen Brookes博士将亲临上海,为您介绍曼彻斯特大学国际医疗领导力在职硕士项目,为您详尽解读课程设计亮点与特色,高度国际化的互动课堂,以及足迹遍布全球的行业资源。

活动详情

时间:18:30-20:30,9月28日,周五

地点:曼彻斯特大学中国中心

          上海市静安区南京西路1376号上海商城西峰604室

活动报名

电话:021-62798660

电邮:IHL@uom.ac.cn

报名链接:http://uom.ac.cn/events/detail/150 


 

曼彻斯特大学中国中心

电话:+86 21 6279 8660

邮箱:IHL@uom.ac.cn; mba@mbs-worldwide.ac.cn

官网:www.uom.ac.cn 

地址:上海市南京西路1376号上海商城604室

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1724988, encodeId=2ec61e24988a0, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Jul 08 01:04:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651575, encodeId=043e16515e50e, content=<a href='/topic/show?id=6e78e32573c' target=_blank style='color:#2F92EE;'>#石墨烯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73257, encryptionId=6e78e32573c, topicName=石墨烯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db924213398, createdName=yangjxjc, createdTime=Tue Feb 05 00:04:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905076, encodeId=764f19050e6b2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Mar 09 09:04:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300191, encodeId=651a1300191b0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391892, encodeId=52f81391892bc, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543654, encodeId=0fd615436547f, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
    2019-07-08 zxxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1724988, encodeId=2ec61e24988a0, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Jul 08 01:04:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651575, encodeId=043e16515e50e, content=<a href='/topic/show?id=6e78e32573c' target=_blank style='color:#2F92EE;'>#石墨烯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73257, encryptionId=6e78e32573c, topicName=石墨烯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db924213398, createdName=yangjxjc, createdTime=Tue Feb 05 00:04:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905076, encodeId=764f19050e6b2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Mar 09 09:04:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300191, encodeId=651a1300191b0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391892, encodeId=52f81391892bc, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543654, encodeId=0fd615436547f, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1724988, encodeId=2ec61e24988a0, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Jul 08 01:04:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651575, encodeId=043e16515e50e, content=<a href='/topic/show?id=6e78e32573c' target=_blank style='color:#2F92EE;'>#石墨烯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73257, encryptionId=6e78e32573c, topicName=石墨烯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db924213398, createdName=yangjxjc, createdTime=Tue Feb 05 00:04:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905076, encodeId=764f19050e6b2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Mar 09 09:04:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300191, encodeId=651a1300191b0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391892, encodeId=52f81391892bc, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543654, encodeId=0fd615436547f, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1724988, encodeId=2ec61e24988a0, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Jul 08 01:04:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651575, encodeId=043e16515e50e, content=<a href='/topic/show?id=6e78e32573c' target=_blank style='color:#2F92EE;'>#石墨烯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73257, encryptionId=6e78e32573c, topicName=石墨烯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db924213398, createdName=yangjxjc, createdTime=Tue Feb 05 00:04:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905076, encodeId=764f19050e6b2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Mar 09 09:04:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300191, encodeId=651a1300191b0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391892, encodeId=52f81391892bc, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543654, encodeId=0fd615436547f, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
    2018-09-22 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1724988, encodeId=2ec61e24988a0, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Jul 08 01:04:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651575, encodeId=043e16515e50e, content=<a href='/topic/show?id=6e78e32573c' target=_blank style='color:#2F92EE;'>#石墨烯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73257, encryptionId=6e78e32573c, topicName=石墨烯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db924213398, createdName=yangjxjc, createdTime=Tue Feb 05 00:04:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905076, encodeId=764f19050e6b2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Mar 09 09:04:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300191, encodeId=651a1300191b0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391892, encodeId=52f81391892bc, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543654, encodeId=0fd615436547f, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1724988, encodeId=2ec61e24988a0, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Mon Jul 08 01:04:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651575, encodeId=043e16515e50e, content=<a href='/topic/show?id=6e78e32573c' target=_blank style='color:#2F92EE;'>#石墨烯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73257, encryptionId=6e78e32573c, topicName=石墨烯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db924213398, createdName=yangjxjc, createdTime=Tue Feb 05 00:04:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905076, encodeId=764f19050e6b2, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Mar 09 09:04:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300191, encodeId=651a1300191b0, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391892, encodeId=52f81391892bc, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543654, encodeId=0fd615436547f, content=<a href='/topic/show?id=509b3418366' target=_blank style='color:#2F92EE;'>#医学研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34183, encryptionId=509b3418366, topicName=医学研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4b713593170, createdName=ms1065684921169360, createdTime=Sat Sep 22 01:04:00 CST 2018, time=2018-09-22, status=1, ipAttribution=)]

相关资讯

BMJ:PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效

由此可见,对于PD-L1阳性和PD-L1阴性的患者,PD-1或PD-L1阻断疗法优于常规疗法。该研究结果表明单独的PD-L1表达状态不足以确定应向哪些患者提供PD-1或PD-L1阻断治疗。

神刊CA:185个国家36种癌症大数据分析!今年将有1000万人死于癌症!

神刊《A Cancer Journal for Clinicians》其影响因子高达244.585,名副其实的学界刊霸,而且CA主要是以肿瘤综述为主,每刊仅有2-5篇综述文章,但其文章质量之高,引用数量之大,是其他顶级期刊都望尘莫及的。2018年9月12日其以“Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and

JAHA:房颤的诊断可增加癌症的发病风险

房颤和癌症均是世界上发病率高的疾病,房颤诊断与癌症后续诊断的时间关联性研究可能有助于找到是否存在共同的致病因素。本研究纳入了丹麦饮食、癌症和健康研究队列中的26222名男性和28879名女性无房颤和癌症的参与者。并对其随访至2013年,观察房颤和癌症的发病情况,男性(平均年龄为56岁)和女性(平均年龄为56岁)的平均随访时间分别为16.7年和19.6年。分析结果显示,房颤的发生与任何类型癌症的发病

癌症的过度治疗比癌症本身更可怕

“过度治疗”,顾名思义,就是超出患者疾病的治疗需求的医疗行为。在癌症的治疗中,过度治疗行为非常普遍。曾有人这样形容,所有因癌症死亡的患者中,三分之一是被吓死的,三分之一是治死的,剩下的三分之一才是真正因病而死。这所谓的“治死”指的就是不恰当的治疗方式,“过度治疗”是典型体现。癌症过度治疗的表现一是盲目追求手术的大和广,鼓励多切除周围的正常组织,手术范围越来越大,或者是在根本无需进行手术的前提下为了

阿司匹林可降低多种癌症的风险

阿司匹林,化学成分为乙酰水杨酸,是一种应用广泛、廉价易得、相对安全的非处方止痛药。阿司匹林经常用于预防中风和血栓。根据多年研究,阿司匹林也可以预防各种癌症。

Sci Adv:多种癌症有望攻克!科学家发现药物治疗又一靶点!

自从研究人员发现了表观遗传和乳腺癌干细胞的联系后,对其在癌症方面的研究便愈来愈热,进展发面更像脱了缰的野马,不断取得突破,来自圣犹达儿童研究医院的遗传学家发现了癌症耐药的另一新靶点——mTORC3,这一发现为新的药物疗法提供了希望,有望可以克服这种耐药性,治疗癌症。